172 related articles for article (PubMed ID: 20596245)
21. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).
Christophersen P; Wulff H
Channels (Austin); 2015; 9(6):336-43. PubMed ID: 26217968
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1.
Srivastava S; Choudhury P; Li Z; Liu G; Nadkarni V; Ko K; Coetzee WA; Skolnik EY
Mol Biol Cell; 2006 Jan; 17(1):146-54. PubMed ID: 16251351
[TBL] [Abstract][Full Text] [Related]
23. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
[TBL] [Abstract][Full Text] [Related]
24. KCa3.1 Channels and Glioblastoma: In Vitro Studies.
Klumpp L; Sezgin EC; Skardelly M; Eckert F; Huber SM
Curr Neuropharmacol; 2018; 16(5):627-635. PubMed ID: 28786347
[TBL] [Abstract][Full Text] [Related]
25. The combined activation of K
Pillozzi S; D'Amico M; Bartoli G; Gasparoli L; Petroni G; Crociani O; Marzo T; Guerriero A; Messori L; Severi M; Udisti R; Wulff H; Chandy KG; Becchetti A; Arcangeli A
Br J Cancer; 2018 Jan; 118(2):200-212. PubMed ID: 29161243
[TBL] [Abstract][Full Text] [Related]
26. Role of KCa3.1 Channels in Modulating Ca
Catacuzzeno L; Franciolini F
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274242
[TBL] [Abstract][Full Text] [Related]
27. Functional expression of mitochondrial K
Bulk E; Todesca LM; Bachmann M; Szabo I; Rieke M; Schwab A
Pflugers Arch; 2022 Nov; 474(11):1147-1157. PubMed ID: 36152073
[TBL] [Abstract][Full Text] [Related]
28. Crocin Improves the Endothelial Function Regulated by Kca3.1 Through ERK and Akt Signaling Pathways.
Yang H; Li X; Liu Y; Li X; Li X; Wu M; Lv X; Chunhua C; Ding X; Zhang Y
Cell Physiol Biochem; 2018; 46(2):765-780. PubMed ID: 29621746
[TBL] [Abstract][Full Text] [Related]
29. Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors.
D'Alessandro G; Limatola C; Catalano M
Curr Neuropharmacol; 2018; 16(5):636-643. PubMed ID: 28707595
[TBL] [Abstract][Full Text] [Related]
30. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration.
Kaushal V; Koeberle PD; Wang Y; Schlichter LC
J Neurosci; 2007 Jan; 27(1):234-44. PubMed ID: 17202491
[TBL] [Abstract][Full Text] [Related]
31. The role of T cell potassium channels, KV1.3 and KCa3.1, in the inflammatory cascade in ulcerative colitis.
Hansen LK
Dan Med J; 2014 Nov; 61(11):B4946. PubMed ID: 25370966
[TBL] [Abstract][Full Text] [Related]
32. Laminar shear stress upregulates endothelial Ca²⁺-activated K⁺ channels KCa2.3 and KCa3.1 via a Ca²⁺/calmodulin-dependent protein kinase kinase/Akt/p300 cascade.
Takai J; Santu A; Zheng H; Koh SD; Ohta M; Filimban LM; Lemaître V; Teraoka R; Jo H; Miura H
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H484-93. PubMed ID: 23792675
[TBL] [Abstract][Full Text] [Related]
33. Ca
Ohya S; Kito H
Biol Pharm Bull; 2018; 41(8):1158-1163. PubMed ID: 30068864
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological targeting of the mitochondrial calcium-dependent potassium channel KCa3.1 triggers cell death and reduces tumor growth and metastasis in vivo.
Bachmann M; Rossa A; Varanita T; Fioretti B; Biasutto L; Milenkovic S; Checchetto V; Peruzzo R; Ahmad SA; Patel SH; Lukowski R; Edwards MJ; Ceccarelli M; Gulbins E; Zoratti M; Mattarei A; Szabo I
Cell Death Dis; 2022 Dec; 13(12):1055. PubMed ID: 36539400
[TBL] [Abstract][Full Text] [Related]
35. Membrane-delimited inhibition of maxi-K channel activity by the intermediate conductance Ca2+-activated K channel.
Thompson J; Begenisich T
J Gen Physiol; 2006 Feb; 127(2):159-69. PubMed ID: 16418402
[TBL] [Abstract][Full Text] [Related]
36. The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells.
Ruggieri P; Mangino G; Fioretti B; Catacuzzeno L; Puca R; Ponti D; Miscusi M; Franciolini F; Ragona G; Calogero A
PLoS One; 2012; 7(10):e47825. PubMed ID: 23110108
[TBL] [Abstract][Full Text] [Related]
37. Role of KCa3.1 Channels in CNS Diseases: A Concise Review.
Sugunan S; Nampoothiri SS; Garg T; Krishnamurthy RG
CNS Neurol Disord Drug Targets; 2016; 15(10):1299-1305. PubMed ID: 27549144
[TBL] [Abstract][Full Text] [Related]
38. K
Bukhari M; Deng H; Sipes D; Ruane-Foster M; Purdy K; Woodworth CD; Sur S; Samways DSK
J Biol Chem; 2021; 296():100084. PubMed ID: 33199365
[TBL] [Abstract][Full Text] [Related]
39. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
Brown BM; Pressley B; Wulff H
Curr Neuropharmacol; 2018; 16(5):618-626. PubMed ID: 28676010
[TBL] [Abstract][Full Text] [Related]
40. Endothelial K
Li JJ; Zhao XY; Wang Y; Xu R; Di XH; Zhang Y; Yang H; Han MZ; Bai RY; Xie L; Pang ZD; Zhang X; Zhang J; Du XJ; Deng XL; Zhang Y; Xie W
Arterioscler Thromb Vasc Biol; 2023 May; 43(5):726-738. PubMed ID: 36951065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
